Dr. Robert M. Langdon, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 973
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: University of Nebraska College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NE license E98503
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Chi Health Bergan Mercy Omaha, NE
- The Nebraska Methodist Hospital Omaha, NE
- Chi Health Lakeside Omaha, NE
- Methodist Jennie Edmundson Council Bluffs, IA
Medical groups
- Oncology Hematology West PC (56 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 973
- Services billed
- 157,577
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 13,960 | 14 |
| Injection, ferric carboxymaltose, 1 mg | 12,750 | 12 |
| Injection, fosaprepitant, 1 mg | 12,000 | 37 |
| Injection, pembrolizumab, 1 mg | 11,203 | 16 |
| Injection, lanreotide, 1 mg | 6,960 | 11 |
| Injection, oxaliplatin, 0.5 mg | 6,600 | 11 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 6,050 | 17 |
| Injection, denosumab, 1 mg | 3,420 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,930 | 66 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,481 | 737 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Omaha, NE | 222 |
| Anastrozole Other prescribers in Omaha, NE | 157 |
| Letrozole Other prescribers in Omaha, NE | 104 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Omaha, NE | 88 |
| Hydroxyurea Other prescribers in Omaha, NE | 70 |
| Ibrance (palbociclib) | 64 |
| Imbruvica (ibrutinib) | 56 |
| Gabapentin Other prescribers in Omaha, NE | 56 |
| Potassium Chloride Other prescribers in Omaha, NE | 53 |
| Eliquis (apixaban) Other prescribers in Omaha, NE | 50 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 21 payments worth $436 in total to this clinician.
| E.r. Squibb & Sons, L.l.c. | $63.89 |
|---|---|
| Recordati_rare_diseases_inc. | $61.08 |
| Genentech, Inc. | $53.45 |
| Servier Pharmaceuticals LLC | $33.65 |
| Gilead Sciences, Inc. | $32.69 |
| AbbVie Inc. | $31.33 |
| Pfizer Inc. | $29.69 |
| Pharmacosmos Therapeutics Inc. | $27.73 |
| Food and Beverage | $382 |
|---|---|
| Education | $53.45 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Oct 7, 2025 | Education in-kind | $53.45 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $251,924 in research payments for these studies, mostly to the institutions running them.
- KEYMAKER-U01 Master Study# A Phase 1,2, Umbrella Study with Rolling Arms of Investigational Agents, Pembrolizumab, and Chemotherapy, Alone or in Combination, in Participants with Non-small Cell Lung Cancer NSCLC
Merck Sharp & Dohme LLC - SERENA 4 A Randomised Multicentre Double Blind Phase 3 Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor Positive HER2 Negativ…
AstraZeneca Pharmaceuticals LP - Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics, Inc. · Active, not recruiting · NCT03785249 - KEYMAKER-U01 Substudy 01A# A Phase 1,2, Umbrella Study With Rolling Arms of Investigational Agents, With Pembrolizumab With or Without Chemotherapy in Treatment-Naive Participants With Stage IV Non-small Cell Lung Can…
Merck Sharp & Dohme LLC - Neoadjuvant NSCLC
Genentech, Inc. - Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT05595460 - KEYMAKER U01 Substudy 3# A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer NSCLC Previously Treated with anti-…
Merck Sharp & Dohme LLC - KEYMAKER U01Substudy 2# A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents in Combination with Pembrolizumab in Treatment Na ve Patients with PD-L1 Positive Advanced Non-Small Cell Lung Cancer NSCLC
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.